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Fleroxacin (Ro 23-6240): activity in vitro against 355
enteropatfaogenic and non-fermentative Gram-negative bacilli and
Legionella pneumophUa
P. HoW*, A. von Graevenitz* and J. Zollinger-Iten*
*F. Hoffmann-La Roche, Pharmaceutical Research, 4002 Basel; and bDepartment of
Medical Microbiology, University of Zurich, 8028 Zurich, Switzerland
The antibacterial activity of fleroxacin (Ro 23-6240, AM-833), a new 6-fluoroquino-
lone, was determined against 149 strains of enteropathogenic bacteria (17 species)
and 191 strains (28 species) of glucose non-fermentative Gram-negative rods
(excluding Pseudomonas aeruginosa), and against IS strains of Legionella
pneumophUa. The cumulative susceptibility of these groups of bacteria to
Ro 23-6240 at the 2 mg/1 level were 99-2%, 801 and 100% of tested strains,
respectively.
Introduction
Fleroxacin (Ro 23-6240, AM-833), in common with other 6-fluoroquinolones, has
been shown to be active against a wide range of Gram-positive and Gram-negative
bacteria (Chin, Brittain & Neu, 1986; Hirai et al., 1986). Up to now its activity against
glucose non-fermentative bacteria and against many of the bacteria causing diarrhoea
has remained undefined. The present study assesses the activity of Ro 23-6240 against
these two diverse groups of potential pathogens, and against Legionella pneumophUa.
Methods
Three hundred and fifty-five strains from the culture collection of the Department of
Medical Microbiology of Zurich University and three control strains (Escherichia coli
ATCC 25922, Pseudomonas aeruginosa ATCC 27853 and Staphylococcus aureus
ATCC 29213) were used in this study. The origins of the glucose non-fermentative
strains and the MIC techniques used in this study have been published previously (von
Graevenitz & Bucher, 1982; National Committee for Clinical Laboratory Standards,
1983).
MICs were determined by standard microbroth serial two-fold dilution methods
(NCCLS, 1983) in Mueller-Hinton broth (MHB) (01 ml) with an inoculum of
approximately 5x10* cfu/well. MBCs were determined by standard methods
(subculture volume 20 ul) and based on a 99-9% (MBQ reduction of the initial
inoculum (Schoenknecht, Sabath & Thornsberry, 1985), as determined by initial and
terminal colony counts for each strain.
•Corresponding author.
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For fastidious strains, the methods and media used for susceptibility testing required
alterations to standard techniques that have not yet been recognized by NCCLS.
Hence, halophilic Vibrio spp. required the addition of 6-5% NaCl to broth for growth.
For the testing of L. pneumophila an agar dilution technique with enriched charcoal-
yeast extract agar was followed (Schoenknecht et al., 1985) with incubation in air plus
10% CO2 at 35°C for 48 h (Edelstein & Meyer, 1980). Campylobacter jejuni underwent
agar dilution testing on Mueller-Hinton agar (MHA) plates (2-5% agar) enriched with
7% horse blood and incubation in an anaerobic jar with an activated gas generating
system but without catalyst at 35°C over 48 h (Wang, Reller & Blaser, 1984). The
control strains included in all such non-standard tests gave results consistent with
those obtained in MHB.
Fleroxacin (Lot No. 0499720, potency 998 /*g/mg) was obtained from an in-house
source, solubilized in 1 ml of methanol and 006 ml sodium hydroxide 1 N in an
ultrasonic bath and diluted in sterile water as needed.
Results
The results of the antibacterial susceptibility determinations of fleroxacin are displayed
in Table I (aetiological agents of diarrhoea) and in Table II (glucose non-fermentative
Gram-negative rods). The cumulative susceptibility of the Enterobacteriaceae and
Vibrionaceae {n = 129) to fleroxacin was 99-2% at the < 2 mg/1 level and 100% at the
4 mg/1 level. The cumulative susceptibility of the 191 non-fermenters to fleroxacin was
801% at sj 2 mg/1, 920% at < 4 mg/1, 98-8% at < 8 mg/1 and 100% at the
< 16 mg/1 level. All L. pneumophila isolates were inhibited by 0-25 mg/1 of fleroxacin.
The MBC of fleroxacin against bacteria causing diarrhoea was usually within one or
two dilution steps of the corresponding MIC value. In contrast, for glucose non-
Table I. In-vitro activity of fleroxacin against causative bacterial agents of diarrhoea
Bacteria
Minimum inhibitory
concentration (MIC) (mg/1)
MICj0 MIC,0 Range
Minimum bactericidal
concentration (MBC) (mg/1)
MBC50MBC90 Range
E. coli (TV = 28)
Aeromonas spp. (TV = 20)
Plesiomonas shigelloides
(TV = 1 0 )
Shigella spp. (TV = 20)
Yersinia spp. (TV^,* = 14)
Y. pseudotuberculosis (N = 3)
Y. kristensenii (TV = 1)
Y. enterolitica {N = 7)
Y. frederiksenii (TV = 3)
Salmonella spp. (TV = 22)
Vibrio spp. (TV = 15)
Camp, jejuni (TV •= 20)
0-06
<006
sgO-06
<006
0125
<0-06
^006
0125
0-125
s£006
sjO-06
0-25
0125
«£006
s£0O6
0125
0-25
0125
<0-06
2
0-25
0-25
0125
1
< 0-06-4
<£ 0-06-0-125
<0-06
< 006-0-25
< 0^)6-2
< 0-06-0-125
<0-06
< 006-2
0125-0-25
s£ 006-0-5
« 006-0125
0-25-1
<006
sSO-06 s
<006
<006
0125
0-25
sSO-06 s
0-25
0125
<0-06
<0-06
0-5
J0O6
0125
0-25
0-25
0-25
^2
0-25
0-25
0125
< 0-06-8
< 0-06-0-125
< 0-06-0-25
<0-06-0-5
^006-2
< 0-06-0-25
^006
< 006-2
0-125-0-25
<0-06-0-5
sj 0-06-0-125
Inoculum of 5 x 10* cfu/well
KUI*, Sum of no. of the different Yersinia species listed immediately below
-, Not done (see Methods).
In-ritro activity of fleroxadn 375
TaWe II. In-vitro activity of fleroxacin against glucose non-fermentative bacteria and
L. pneumophila
Bacteria
Ps. maltophilia (N = 10)
Ps. acidovorans (N = 5)
Ps. alcaligenes (N = 5)
Ps. pseudoalcaligenes (N = 7)
Ps. stutzeri (N = 8)
Ps. pseudomallei (N = 6)
Ps. cepacia (N •= 9)
Ps. putida (N = 8)
Ps. putrefaciens (N = 4)
Ps. fluorescent (N •= 10)
Ps. mendocina (N = 3)
Ps. pickettii VA-2 (W •= 7)
Ps. vesicularis (N =• 4)
Ps. diminuta (N = 6)
Ps. K4-7 ( # = 7)
Ps. K£ (W » 8)
Flavobacterium II-B (W = 8)
F. multivorum (N = 5)
F. odoratum (N = 6)
F. meningosepticum (N = 5)
CZ>C Group //-/• ( # = 6)
Acinetobacter calcoaceticus
subspecies anitratus (N = 12)
subspecies /H-O#H ( # = 8)
Alcaligenes denitrificans (N = 4)
Ale. faecalis (N = 4)
Ale. odorans (N = 4)
Achromobacter VD (N = 8)
/4cA. xylosoxidans (N •= 8)
Moraxella urethralis (N = 6)
L. pneumophila (N = 15)*
Minimum
concentration
MICJO
4
0-25
<006
0-25
<006
4
4
2
0-25
0-5
<006
2
0-25
4
2
0-25
1
1
2
4
2
0-5
0125
2
^006
0-5
0-5
2
0125
0125
MIC,0
4
2
0-5
16
0-5
8
8
4
1
0-5
0-25
2
8
8
2
2
4
8
4
16
4
0-5
1
4
1
1
1
8
0-5
0-25
inhibitory
(MIC) (mg/1)
Range
2-8
< 006-2
<006-O-5
<006-16
sSO-06-0-5
4-8
2-8
0-5-4
<006-l
0-125-1
sj 0-06-0-25
0-5-2
0-25-8
4-8
0-5-2
sj 0-06-2
0-5-4
0-5-8
2-4
2-16
0-5-^
<0-06-0-5
sjO-06-1
< 0-06-4
sj 0-06-1
sj 0-06-1
0-125-1
1-8
0125-0-5
0-06-0-25
Minimum bactericidal
concentration
MBCJ0
8
0-25
sSO-06
0-5
0-25
16
8
4
0-5
1
0-25
2
0-25
4
4
0-25
1
1
32
32
8
0-5
0-5
4
0125
1
1
4
0-5
-
MBC90
16
2
0-5
16
1
32
16
8
4
2
0-5
4
8
8
4
2
4
8
64
>128
64
1
2
32
16
2
2
16
2
-
(MBC) (mg/1)
Range
4-16
< 0-06-2
< 0-06-0-5
0125-16
*S 0-06-1
16-32
2-16
1-8
0-125-^
0-25-2
<0-06-0-5
\^X
0-25-8
4-8
0-5-4
«: 0-06-2
0-5-4
0-5-8
4-64
4->128
2-64
«S0-06-l
<g 0-06-2
1-32
s£ 0-06-16
1-2
0-125-2
4-16
0-125-2
-
Inoculum of 5 x 10* cfu/well.
•Agar dilution test using enriched CYE agar, incubation at 35°C over 48 h in COj. MBC test not
available.
-, Not done.
fermentative rods the ninetieth percentile of the MBC was frequently identical to that
of the MIC. However, for five of 29 species and subspecies tested with fleroxacin the
MBC90 exceeded the MIC90 by three or more dilution steps. With application of a less
stringent MBC definition that required the reduction of the inoculum 100-fold (rather
than the customary 1000-fold), the resulting MBC90s were mostly identical or lower by
two than those reported above (data not shown).
The three control strains (E. coli ATCC 25922, Staph. aureus ATCC 29213, Ps.
aeruginosa ATCC 27853) used in this trial yielded uniform MIC values to fleroxacin,
with ranges of < 006, 0-5—1 and 2-4, respectively. These values were consistent with
those found previously in our laboratory (unpublished data). Under the special
conditions employed to test the activity of fleroxacin against Camp.jejuni and
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L. pneumophila, the MIC values of E. coli ATCC 25922 were 006 mg/1 and 0-25 mg/1,
respectively.
Discussion
In the present study, fleroxacin proved to be active against Enterobacteriaceae and
other bacterial species that cause diarrhoea. Fleroxacin—in common with other
quinolones—was very potent against all enteropathogenic bacteria tested, possibly even
more so weight for weight than all /Mactam agents other than imipenem, co-
trimoxazole, tetracyclines and the two compounds with mainly intraluminal activity,
bismuth subsalicylate and furazolidone. Fleroxacin concentrations of 2 or 4 mg/1
(inhibitory against 99-2 and 100% of strains, respectively), have been shown to be
clinically attainable in urine with a single oral dose of 400 mg and in plasma and
tissue fluid with an oral dose of 800 mg (Weidekamm, Stockel & Dell, 1987). Against
the commonly encountered enteropathogens our results with fleroxacin are consistent
with those of other authors (Carlson et al, 1983; Fass, 1985; Chin et al.. 1986) who
have evaluated the new quinolones.
The activity of fleroxacin was not influenced by production (9 strains) or not (3
strains) of enterotoxin in E. coli. The compound was invariably active against Shigella
sonnei (7), Sh.flexneri (7) and Sh. boydii (5), as well as Sh. dysenteriae (1). Non-typhi
salmonellae (13) were as susceptible as Salmonella typhi (9).
No noteworthy differences emerged between the different Vibrio spp. tested
(V. cholerae (5), V. parahaemolyticus (5) and V. alginolyticus (5)). Of the Yersinia spp.,
one isolate of Y. enterocolitica (7) was at least eight-fold more resistant than the
others. Some of the more unusual species tested have only recently been recognized as
enteropathogenic bacteria, i.e. Y. kristensenii (1) (Baier & Ruppel, 1981),
Y. frederiksenii (3) (Baier & Puppel, 1981), Y. pseudotuberculosis (3) (Tertti et al.,
1984), V. alginolyticus (5) (Joseph, Colwell & Kaper, 1982), V. parahaemolyticus (5)
(Joseph et al., 1982) and Aeromonas hydrophila (Holmberg & Farmer, 1984). For
reasons not well understood, all quinolones including fleroxacin (data on file) are as
inactive against Clostridium difficile (Fass, 1985) as they are against many other
anaerobic bacilli.
On the strength of the antibacterial activity demonstrated, fleroxacin should be
effective in the treatment and prophylaxis of both diarrhoea and septicaemias caused
by Salmonella spp. or Campylobacter spp. Comparative trials with erythromycin and a
placebo against Camp, jejuni should determine the place of fleroxacin in Camp, jejuni
infections. Likewise, clinical trials with fleroxacin and standard comparative
compounds and/or placebo should be undertaken in all forms of gastrointestinal
disease due to other enteropathogenic bacteria susceptible to fleroxacin in vitro.
Indeed, the combination of high systemic and intraluminal activity of quinolones
suggests that the prophylaxis and treatment of gastrointestinal infections could be a
major indication for fleroxacin and its congeners.
The present study also provides new information on the activity of fleroxacin against
glucose non-fermentative Gram-negative bacteria. Although it is about eight-fold less
active on a weight-by-weight basis than ciprofloxacin (99% of isolates susceptible to
< 1 mg/1; Husson et al, 1985), the higher plasma levels of fleroxacin and the lack of
side effects for single doses of up to 1500 mg orally in volunteers (Weidekamm et al.,
1987) imply that fleroxacin could have a role in the treatment of infections brought
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about by these unusual pathogens, particularly if they involve the urinary tract.
However, ciprofloxacin is also very active against these same organisms (Baier &
Puppel, 1981; Grimm, 1985)). Ultimately, more information on the side effects of
fleroxacin as well as a comparative in-vitro study will be needed to decide whether
fleroxacin or ciprofloxacin is tolerated better and is more active in vivo (Neu & Ellner,
1983) against these isolates.
An additional advantageous feature of fleroxacin was that its bactericidal activity
remained within one or two dilution steps of its inhibitory activity for all but a few
strains. This asset—if clinically significant—could prove especially useful against non-
fermentative organisms in the immunosuppressed. This finding is not unique to
fleroxacin but is shared by all 6-fluoroquinolones.
Fleroxacin was also active in vitro against L. pneumophila. There is experimental
evidence that this might be clinically significant because quinolones including
fleroxacin are known to diffuse into murine macrophages where they attain levels two-
to three-fold higher than in serum or tissue fluids (Easmon & Crane, 1985).
All the above findings on fleroxacin combined with its high bactericidal activity, the
fact that it is well tolerated and has an elimination half-life (T]pJ?) in excess of 9 h
suggest that this new quinolone possesses features that are desirable in any new
antibacterial about to enter clinical evaluation.
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